SCHEMBL32677770

CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O

nearest known ligand 0.58

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	CAPN1	P07384	2/20	0.58

▸	CTSB	P07858	2/20	0.58

▸	GLP1R	P43220	16/20	0.56

▸	GIPR	P48546	16/20	0.56

▸	CXCR4	P61073	2/20	0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL32677767	1.00	CAPN1 (0.58)	CAPN1CTSBGLP1RGIPRCXCR4
SCHEMBL29520100	0.92	CXCR4 (0.59)	CAPN1CTSBGLP1RGIPRCXCR4
SCHEMBL29682933	0.91	GLP1R (0.62)	GLP1RGIPRCXCR4
SCHEMBL32677743	0.91	CXCR4 (0.52)	CAPN1CTSBCXCR4
SCHEMBL31156960	0.90	CXCR4 (0.61)	GLP1RGIPRCXCR4
SCHEMBL31058451	0.90	CXCR4 (0.52)	CAPN1CTSBGLP1RGIPRCXCR4
SCHEMBL29669247	0.90	CXCR4 (0.60)	GLP1RGIPRCXCR4
SCHEMBL30647310	0.89	GLP1R (0.65)	GLP1RGIPR
SCHEMBL30647305	0.89	GLP1R (0.65)	GLP1RGIPR
SCHEMBL30647309	0.89	GLP1R (0.66)	GLP1RGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20260055154-A1	LONG-ACTING DUAL-AGONIST COMPOUND	CHENGDU AODA BIOTECHNOLOGY CO LTD (CN)	2026-02-26	—	—	US	claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20260055154-A1	LONG-ACTING DUAL-AGONIST COMPOUND	GIPR, GLP1R, GCG	CAPN1 2622/4885CTSB 1792/4885GLP1R 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.